Advertisement
GNLX 外汇新闻
Genelux Says FDA Grants Fast Track Designation For Olvi-Vec To Treat Ovarian Cancer
Immuno-oncology company Genelux Corp. (GNLX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.
RTTNews
|
558天前
Genelux Appoints Lourie Zak As New CFO
Immuno-oncology company Genelux Corp. (GNLX) announced Monday that Lourie Zak will join the company as Chief Financial Officer, effective August 28, 2023.
RTTNews
|
649天前
